This was revealed in an article published in The Lancet Global Health. Today, the African continent is hardest hit by the development of antimicrobial resistance (AMR), marking a turning point in the health challenges faced by the region. A reality that calls for an urgent response. Dr. Daouda Sissoko, infectious disease specialist and Medical Director for bioMérieux Afrique, discusses the causes and consequences of this major public-health issue.

In 2020, vaccine research received significant attention as researchers were engaged in the race to develop an effective vaccine against SARS-CoV-2 worldwide. More broadly, the entire pharmaceutical industry is experiencing this rapid growth. In this context, supply chain sustainability is crucial. The use of horseshoe crab blood in the quality and safety control process is essential to ensure the safety of injectable and implantable pharmaceutical products. Environmental challenges are key in the debate around the use of traditional Limulus Amebocyte Lysate (LAL) methods in favor of more sustainable methods such as recombinant Factor C (rFC).

Antimicrobial resistance (AMR) is a global threat to public health, with deaths attributed to resistant infections projected to exceed ten million per year by 2050.1 The rapid evolution of resistance requires early identification of patients at risk followed by administration of appropriate empiric antibiotic therapy. Collaboration between stewardship teams and the microbiology lab can play a critical role with the implementation of modern antibiograms that support a clinician’s choice of optimal antimicrobial therapy sooner.

Clinical labs are often faced with the challenge of needing to be better, faster, and more productive – while sometimes expected to do so with fewer resources and contending with supply chain issues. With the continued focus on value-based care as a main objective in healthcare, optimizing the utilization of diagnostic testing is more important than ever.